SynthesisHerz2020
Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations.
Synthesis in Herz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06153433 (Clinical Trial to Evaluate the Efficacy and Safety of Suvaro®OD Tablet in Patients With Dyslipidemia), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Trial to Evaluate the Efficacy and Safety of Suvaro®OD Tablet in Patients With Dyslipidemia
Open the trial in the graphWho cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis.Journal of comparative effectiveness research · 2023Pooled it
- Trial
- Comparing rosuvastatin and atorvastatin on cardiovascular and kidney outcomes in patients with diabetes across chronic kidney disease stages: an emulated target trial in China.EClinicalMedicine · 2026Article
- Effects of rosuvastatin and atorvastatin treatment on ET-1, ADMA, and safety efficacy in elderly patients with coronary heart disease combined with hyperlipidemia.Open life sciences · 2026Article
- Efficacy and Safety of Evolocumab in Improving Low-Density Lipoprotein Cholesterol (LDL-C) Levels in a Japanese Population - Systematic Review and Meta-Analysis.Circulation reports · 2025Article
- Lipid Lowering Therapy on Coronary Artery Plaque in East Asians: The Lower the Better.JACC. Asia · 2025Article
- Comparative Effectiveness of Rosuvastatin Versus Atorvastatin in Acute Ischemic Stroke Treatment.Journal of the American Heart Association · 2025Article
- Effects of Trimetazidine Combined with Atorvastatin on Cardiac Function in Patients with Stable Angina Pectoris of Coronary Heart Disease.International journal of general medicine · 2025Article
- PCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report.Frontiers in cardiovascular medicine · 2025Article
- Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells.Scientific reports · 2024Article
- Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study.Pharmacy (Basel, Switzerland) · 2024Article
- The impact of statin use on short-term and long-term mortality in patients with heart failure.Frontiers in pharmacology · 2024Article
- Rosuvastatin suppresses TNF-α-induced matrix catabolism, pyroptosis and senescence via the HMGB1/NF-κB signaling pathway in nucleus pulposus cells.Acta biochimica et biophysica Sinica · 2023Article
- Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study.Journal of clinical medicine · 2023Article
- Cardiovascular disease preventive effects of aspirin combined with different statins in the United States general population.Scientific reports · 2023Article
- An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Article
- National Trends in Statin Use in Lithuania from 2010 to 2021.Medicina (Kaunas, Lithuania) · 2022Article
- Statin Prescription Patterns and Associations with Subclinical Inflammation.Medicina (Kaunas, Lithuania) · 2022Article
- Efficacy of Rosuvastatin Combined with rt-PA Intravenous Thrombolytic Therapy for Elderly Acute Ischemic Stroke Patients.Computational and mathematical methods in medicine · 2022Article
- Plausible Positive Effects of Statins in COVID-19 Patient.Cardiovascular toxicology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe VOYAGER meta-analysis reported on the low-density lipoprotein cholesterol (LDL-C)-lowering effect of commonly used statins in Caucasian subjects. As there is limited literature available on the efficacy of statins in Asian populations, the current meta-analysis compared the effects of rosuvastatin and atorvastatin on LDL-C levels in an East Asian population.
methodsThe MEDLINE, PubMed, Embase, Cochrane Library, and Web of Science databases were searched for randomized controlled trials comparing lipid-lowering effects of rosuvastatin and atorvastatin in an East Asian population. Data on the study design, participant characteristics, and outcomes were extracted. Odds ratios (OR), weighted mean differences (WMD), or standardized mean differences were calculated using the random-effects model.
resultsThe meta-analysis comprised 16 randomized controlled trials with 5930 participants. Compared with atorvastatin, patients treated with rosuvastatin had a significant reduction in LDL-C: WMD = -7.15 mg/dl (95% confidence intervals [CI]: -10.71--3.60) mg/dl, p < 0.0001. Meta-regression analyses revealed no significant association between the superior benefits of rosuvastatin and other variables including age, sex, baseline LDL-C level, and follow-up duration. Additionally, the rosuvastatin group of patients, who were treated with half the dose of atorvastatin, achieved a significantly greater reduction in LDL-C levels (WMD = -3.57; 95% CI: -5.40--1.74 mg/dl, p < 0.001). Both rosuvastatin and atorvastatin were well tolerated, with similar incidences of adverse events.
conclusionSimilar to the VOYAGER meta-analysis, which reported a greater efficacy of rosuvastatin in comparison with atorvastatin and simvastatin in Caucasian patients, we found that the efficacy of rosuvastatin was superior to atorvastatin in East Asian patients with hypercholesterolemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.